Recursion Pharmaceuticals (RXRX) After Phase 2 Data What The REC 4881 Narrative Means For Valuation

Simply Wall St.11-09

Recursion Pharmaceuticals (RXRX) just put fresh Phase 2 data for its REC-4881 program in front of investors, highlighting sizable polyp burden reductions in familial adenomatous polyposis patients and...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2682821872?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-11-09 06:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2682821872","market":"sg","top_or_hot":-1,"title":"Recursion Pharmaceuticals (RXRX) After Phase 2 Data What The REC 4881 Narrative Means For Valuation","media":"Simply Wall St.","content":"<div>\n<p>Recursion Pharmaceuticals (RXRX) just put fresh Phase 2 data for its REC-4881 program in front of investors, highlighting sizable polyp burden reductions in familial adenomatous polyposis patients and...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-pharmaceuticals-rxrx-after-phase-2-data-what-the-r\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Recursion Pharmaceuticals (RXRX) After Phase 2 Data What The REC 4881 Narrative Means For Valuation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecursion Pharmaceuticals (RXRX) After Phase 2 Data What The REC 4881 Narrative Means For Valuation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-09 06:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-pharmaceuticals-rxrx-after-phase-2-data-what-the-r><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recursion Pharmaceuticals (RXRX) just put fresh Phase 2 data for its REC-4881 program in front of investors, highlighting sizable polyp burden reductions in familial adenomatous polyposis patients and...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-pharmaceuticals-rxrx-after-phase-2-data-what-the-r\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-pharmaceuticals-rxrx-after-phase-2-data-what-the-r","article_id":"2682821872","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-pharmaceuticals-rxrx-after-phase-2-data-what-the-r","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2682821872","pubTimestamp":1794176267,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BBailey PembertonNovember 8, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","RXRX":"Recursion Pharmaceuticals, Inc.","BK4139":"生物科技","BK4611":"AI医疗","BK4539":"次新股","BK4609":"英伟达持仓股"},"translate_title":"Recursion Pharmaceuticals (RXRX) 第二阶段数据后 REC 4881 叙述对估值意味着什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":1.97},"content_text":"Recursion Pharmaceuticals (RXRX) just put fresh Phase 2 data for its REC-4881 program in front of investors, highlighting sizable polyp burden reductions in familial adenomatous polyposis patients and a clean safety profile that supports a planned registrational trial. The fresh REC-4881 data lands after a volatile stretch for Recursion Pharmaceuticals, with the share price down 19.3% over the past month and 16.2% year to date, yet still up 7% on a 90 day view as traders weigh earlier earnings and the recent board change alongside this new clinical readout. Scan how Recursion Pharmaceuticals stacks up against other biotech stories with fresh catalysts by reviewing a curated list of 35 healthcare AI stocks. Recursion Pharmaceuticals is trading well below its recent range after the REC-4881 update and board shake up. Is most of the value of this pipeline already reflected in the US$3.52 quote, or is meaningful upside still ahead? AdvertisementMost Popular Narrative: 52% Undervalued At a last close of $3.52 versus a narrative fair value of $7.32, Recursion Pharmaceuticals is framed as materially discounted, with the thesis hinging on how well the platform, pipeline and partnerships convert into future cash flows under a 7.49% discount rate.  The key thing that has to go right is that Recursion Pharmaceuticals turns its AI-driven platform and growing pipeline, including partnered programs with Roche, Genentech, and Sanofi, into commercially meaningful assets while keeping operating expenses in line with guidance. The current valuation implies the market is still discounting the potential of Recursion Pharmaceuticals’ AI-enabled pipeline and partnership economics despite clinical progress, sizeable milestone structures, and a cash runway that management projects into early 2028.  See why 143 investors see Recursion Pharmaceuticals as 52% undervalued. Result: Fair Value of $7.32 (UNDERVALUED) Still, the Recursion Pharmaceuticals story can change quickly if the timing of milestone revenue remains choppy or if further equity raises dilute existing holders again. Find out about the key risks to this Recursion Pharmaceuticals narrative. Another View on Recursion Pharmaceuticals Valuation The SWS DCF model points in the opposite direction to the rich P/S multiples. RXRX is trading at $3.52, which is 57.1% below the modelled future cash flow value of $8.21, so the framework identifies the stock as undervalued. Which signal should investors prioritize when the cash flows are still years away? Look into how the SWS DCF model arrives at its fair value. RXRX Discounted Cash Flow as at Nov 2026Next Steps Plenty of optimism and concern sit side by side in the Recursion Pharmaceuticals story right now. Consider moving quickly, review the numbers for yourself, and weigh both the upside and the risks by checking the 1 key reward and 3 important warning signs. Looking for more investment ideas beyond Recursion Pharmaceuticals? Do not stop your research with Recursion Pharmaceuticals. Broaden your watchlist with fresh ideas sourced from structured screeners that focus on quality, resilience, and income potential.  Target potential upside by scanning a curated set of high quality opportunities through the 19 high quality undiscovered gems. Strengthen portfolio resilience by focusing on companies with dependable finances using the list of solid balance sheet and fundamentals (25 results). Build a reliable income stream by reviewing businesses offering robust payout profiles via the 7 dividend fortresses.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2682821872","isCrawlerRequest":true}